Hogan Lovells Fidelity (Shanghai)

Qing Lyu

Hogan Lovells Fidelity (Shanghai)
Senior Associate

Qing Lyu is a senior associate at Hogan Lovells Fidelity, Shanghai. She started her professional career in Hogan Lovells in Beijing in 2013. Afterwards, she studied in the LL.M. program of the Georgetown University Law Centre with a focus on antitrust law. In 2017, she re-joined Hogan Lovells Washington D.C. Office where she worked closely with the U.S. antitrust group and international trade group. Currently based in Shanghai, her practice spans across various industries such as high-tech, media and telecom, chemical, shipping and manufacturing. She has advised Chinese and multinational companies in antitrust law matters, including merger control filings, conduct investigations, regulatory compliance and policy analysis.

Auteurs associés

Hogan Lovells (Madrid)
Hogan Lovells (London)
Hogan Lovells (London)
Hogan Lovells (Washington)
Hogan Lovells (Washington)


2193 Bulletin

Adrian Emch, Qing Lyu The Chinese Competition Authority’s local office approves a landmark joint venture transaction to herald the implementation of the pilot merger control devolution which empowers the Authority’s local offices to conduct merger review for simple cases (FAW / Refire)


Yesterday, on 29 August 2022, clearance for the FAW/Refire joint venture transaction was announced on one of the websites of the Chinese antitrust authority – i.e., the State Administration for Market Regulation. That transaction marks the first case where Chinese merger review was handled by (...)

Suyu Yuan, Adrian Emch, Qing Lyu The Nanjing Intermediate People’s Court rules in favour of an undertaking and its subsidiary in an abuse of dominance case against its suppliers of active pharmaceutical ingredient and awards the plaintif damages as compensation for anti-competitive conduct totally $10 million (Yangtze River)


On 18 March 2020 the Nanjing Intermediate People’s Court (court) ruled in favor of Yangtze River Pharmaceutical Group and its subsidiary (Yangtze Pharma) in an abuse of dominance case against its suppliers of active pharmaceutical ingredients (API). The court awarded the plaintiffs a record (...)

Adrian Emch, Rachel Xu, Andrew McGinty, Qing Lyu, Jun Wei The Chinese State Administration for Market Regulation releases a draft with proposed amendments to the Chinese Anti-Monopoly Law


CHINA TABLES FIRST SET OF AMENDMENTS TO THE ANTI-MONOPOLY LAW* On 2 January 2020, China’s antitrust authority – the State Administration for Market Regulation (’SAMR’) – released a draft proposing amendments to the main antitrust statute in China, the Anti-Monopoly Law (’AML’), for public (...)

Suyu Yuan, Adrian Emch, Rachel Xu, Qing Lyu The Chinese Supreme Court rules that Chinese antitrust authorities do not have to prove the anti-competitive effects of companies’ resale price maintenance conduct (Hainan Yutai Technology Feed)


NEITHER FISH NOR FOWL – CHINA’S SUPREME COURT PROPOSES NEW FRAMEWORK FOR RESALE PRICE MAINTENANCE* In the last week of June 2019, a copy of a ground-breaking court ruling emerged on social media in China – the order by the Supreme People’s Court (SPC) in the case between Yutai Technology (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message